Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.24.00279 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von David J Einstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Prostatic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.
Abstract (Originalsprache)
What is most important to patients with BCR prostate cancer? Metastasis-free versus treatment-free survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
- Harvard Medical School, Boston, MA.
- Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA.
- Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA.
- Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
ORCID-Profile: David J Einstein
Förderung
- Intramural NIH HHS
Zitieren
APA
Einstein, D. J., Regan, M. M., Stevens, J. S., McDermott, D. F., & Madan, R. A. (2024). Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00279
Vancouver
Einstein DJ, Regan MM, Stevens JS, McDermott DF, Madan RA. Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00279
BibTeX
@article{Einstein2024,
author = {Einstein, David J and Regan, Meredith M and Stevens, Julia S and McDermott, David F and Madan, Ravi A},
title = {Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.24.00279}
}
EUVIMED